tiprankstipranks
Blurbs

Dawson James Sticks to Their Buy Rating for 22nd Century (XXII)

In a report released on September 21, James McIlree from Dawson James maintained a Buy rating on 22nd Century (XXIIResearch Report), with a price target of $8.50. The company’s shares closed last Friday at $0.97.

According to TipRanks, McIlree is an analyst with an average return of -21.7% and a 26.32% success rate. McIlree covers the Technology sector, focusing on stocks such as Vuzix, SRAX, and Smith Micro Software.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for 22nd Century with a $6.17 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $3.52 and a one-year low of $0.94. Currently, 22nd Century has an average volume of 2.24M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

22nd Century Group, Inc. is a plant biotechnology company, which engages in the development of technology that will allow to increase or decrease the level of nicotine and nicotinic alkaloids in tobacco plants and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. Its products include X-22, modified risk cigarettes, spectrum government research cigarettes, magic 0 and magic 2, moonlight, red sun, variable nicotine-level research cigarettes, and verfola. The company was founded on September 12, 2005 and is headquartered in Clarence, NY.

Read More on XXII:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles